Showing results (791-800 of 857) with videos related to

Sort By:
Pageof 86
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Nature Reviews. Nephrology|January 30, 2019
C3 glomerulopathy - understanding a rare complement-driven renal diseaseRichard J H Smith, Gerald B Appel, Anna M Blom, et al.
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
BMJ Open|September 25, 2012
Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USAPaolo Cravedi, Sanjib Kumar Sharma, Rodolfo Flores Bravo, et al.
European Journal of Preventive Cardiology|May 9, 2021
Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990-2017Paolo A Cortesi, Carla Fornari, Fabiana Madotto, et al.
Annals of Internal Medicine|July 1, 2024
Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease : A Systematic Review and Retrospective Individual Participant-Level Meta-analysis of Clinical TrialsElaine Ku, Lesley A Inker, Hocine Tighiouart, et al.
The Lancet. Global Health|April 23, 2016
Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional studyBogdan Ene-Iordache, Norberto Perico, Boris Bikbov, et al.
The New England Journal of Medicine|July 16, 2011
MYO1E mutations and childhood familial focal segmental glomerulosclerosisCaterina Mele, Paraskevas Iatropoulos, Roberta Donadelli, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Kidney International Reports|December 18, 2023
Efficacy and Safety of Iptacopan in Patients With C3 GlomerulopathyEdwin Wong, Carla Nester, Teresa Cavero, et al.
Pageof 86